Drug intelligence / Profile preview

ocrelizumab + alarelin

Development stage: Phase 4
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

This is a combination of two drugs, ocrelizumab and alarelin. Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B lymphocytes, leading to their depletion; it is primarily used as an immunosuppressive therapy for multiple sclerosis. Alarelin is a synthetic gonadotropin-releasing hormone (GnRH or LHRH) agonist peptide, mainly used in veterinary medicine to induce ovulation by stimulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). There are no known approved or investigational uses for this specific combination in humans or animals.

Targets

CD20 (B-lymphocyte antigen CD20)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on ocrelizumab + alarelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ocrelizumab + alarelin.

Explore the full profile